Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.43 (market cap $6.04B), while First Trust NASDAQ 100 Technology Index Fund trades at $330.53 (market cap $4.10B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and First Trust NASDAQ 100 Technology Index Fund is more actively traded (264,303 versus 14,805,993). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| IOVA | QTEC | |
|---|---|---|
Market Cap | $6.04B | $4.10B |
Volume | 14,805,993 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $14.82 | $340.28 |
52-Week Low | $1.81 | $207.03 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $335.82, down 1.31% on the day. Technical indicators show a bullish trend from moving averages but caution from overbought RSI levels. The ETF provides equal-weighted exposure to the technology sector, with recent analysis highlighting its broader sector definition and liquidity advantages.
The outlook for QTEC is supported by bullish technical trends and its role in tech exposure, though overbought conditions and sector volatility present risks. Investment opportunity lies in diversified tech access, but investors face market sensitivity and valuation pressures inherent to technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
